25 XP   0   0   10

Syndax Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Syndax together

PenkeI guess you are interested in Syndax Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Syndax Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Syndax Pharmaceuticals Inc

I send you an email if I find something interesting about Syndax Pharmaceuticals Inc.

Quick analysis of Syndax (30 sec.)










What can you expect buying and holding a share of Syndax? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$6.52
Expected worth in 1 year
$7.54
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$1.02
Return On Investment
5.0%

For what price can you sell your share?

Current Price per Share
$20.57
Expected price per share
$15.90 - $24.84
How sure are you?
50%

1. Valuation of Syndax (5 min.)




Live pricePrice per Share (EOD)

$20.57

Intrinsic Value Per Share

$-21.93 - $-13.34

Total Value Per Share

$-15.41 - $-6.82

2. Growth of Syndax (5 min.)




Is Syndax growing?

Current yearPrevious yearGrowGrow %
How rich?$554.1m$385.5m$51.7m11.8%

How much money is Syndax making?

Current yearPrevious yearGrowGrow %
Making money-$51.1m-$36.7m-$14.3m-28.2%
Net Profit Margin-3,380.3%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Syndax (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#96 / 1010

Most Revenue
#619 / 1010

Most Profit
#892 / 1010

Most Efficient
#880 / 1010

What can you expect buying and holding a share of Syndax? (5 min.)

Welcome investor! Syndax's management wants to use your money to grow the business. In return you get a share of Syndax.

What can you expect buying and holding a share of Syndax?

First you should know what it really means to hold a share of Syndax. And how you can make/lose money.

Speculation

The Price per Share of Syndax is $20.57. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Syndax.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Syndax, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.52. Based on the TTM, the Book Value Change Per Share is $0.26 per quarter. Based on the YOY, the Book Value Change Per Share is $0.17 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Syndax.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.85-4.1%-0.62-3.0%-0.44-2.1%-0.27-1.3%-0.25-1.2%
Usd Book Value Change Per Share2.3011.2%0.261.2%0.170.8%0.291.4%0.160.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share2.3011.2%0.261.2%0.170.8%0.291.4%0.160.8%
Usd Price Per Share21.61-19.55-21.53-16.92-11.65-
Price to Earnings Ratio-6.33--8.31--12.26--12.30--10.56-
Price-to-Total Gains Ratio9.42--31.78--60.56--40.32--42.57-
Price to Book Ratio3.31-3.83-4.78-8.20-7.18-
Price-to-Total Gains Ratio9.42--31.78--60.56--40.32--42.57-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share20.57
Number of shares48
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.260.29
Usd Total Gains Per Share0.260.29
Gains per Quarter (48 shares)12.2514.16
Gains per Year (48 shares)49.0156.62
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10493905747
2098880113104
301471370170161
401961860226218
502452350283275
602942840340332
703433330396389
803923820453446
904414310510503
1004904800566560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%1.040.00.02.4%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%7.013.00.035.0%11.027.02.027.5%12.027.02.029.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%1.00.040.02.4%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%7.013.00.035.0%11.027.02.027.5%12.027.02.029.3%

Fundamentals of Syndax

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-12 18:41:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Syndax Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Syndax earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Syndax to the Biotechnology industry mean.
  • A Net Profit Margin of -13,521.1% means that $-135.21 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Syndax Pharmaceuticals Inc:

  • The MRQ is -13,521.1%. The company is making a huge loss. -2
  • The TTM is -3,380.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-13,521.1%TTM-3,380.3%-10,140.8%
TTM-3,380.3%YOY--3,380.3%
TTM-3,380.3%5Y-3,051.9%-328.3%
5Y-3,051.9%10Y-3,780.2%+728.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13,521.1%-207.2%-13,313.9%
TTM-3,380.3%-216.8%-3,163.5%
YOY--282.3%+282.3%
5Y-3,051.9%-436.8%-2,615.1%
10Y-3,780.2%-597.3%-3,182.9%
1.1.2. Return on Assets

Shows how efficient Syndax is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Syndax to the Biotechnology industry mean.
  • -11.8% Return on Assets means that Syndax generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Syndax Pharmaceuticals Inc:

  • The MRQ is -11.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.8%TTM-10.7%-1.1%
TTM-10.7%YOY-8.8%-1.9%
TTM-10.7%5Y-9.8%-0.9%
5Y-9.8%10Y-15.6%+5.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.8%-13.3%+1.5%
TTM-10.7%-12.8%+2.1%
YOY-8.8%-11.6%+2.8%
5Y-9.8%-13.8%+4.0%
10Y-15.6%-15.6%0.0%
1.1.3. Return on Equity

Shows how efficient Syndax is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Syndax to the Biotechnology industry mean.
  • -13.1% Return on Equity means Syndax generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Syndax Pharmaceuticals Inc:

  • The MRQ is -13.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.1%TTM-11.7%-1.4%
TTM-11.7%YOY-9.7%-2.0%
TTM-11.7%5Y-14.0%+2.3%
5Y-14.0%10Y-23.2%+9.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.1%-16.9%+3.8%
TTM-11.7%-16.1%+4.4%
YOY-9.7%-14.9%+5.2%
5Y-14.0%-19.3%+5.3%
10Y-23.2%-20.1%-3.1%

1.2. Operating Efficiency of Syndax Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Syndax is operating .

  • Measures how much profit Syndax makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Syndax to the Biotechnology industry mean.
  • An Operating Margin of -13,509.3% means the company generated $-135.09  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Syndax Pharmaceuticals Inc:

  • The MRQ is -13,509.3%. The company is operating very inefficient. -2
  • The TTM is -3,377.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-13,509.3%TTM-3,377.3%-10,132.0%
TTM-3,377.3%YOY--3,377.3%
TTM-3,377.3%5Y-3,025.9%-351.5%
5Y-3,025.9%10Y-3,598.5%+572.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13,509.3%-298.0%-13,211.3%
TTM-3,377.3%-238.5%-3,138.8%
YOY--288.4%+288.4%
5Y-3,025.9%-486.2%-2,539.7%
10Y-3,598.5%-628.4%-2,970.1%
1.2.2. Operating Ratio

Measures how efficient Syndax is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 145.85 means that the operating costs are $145.85 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Syndax Pharmaceuticals Inc:

  • The MRQ is 145.845. The company is inefficient in keeping operating costs low. -1
  • The TTM is 36.461. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ145.845TTM36.461+109.384
TTM36.461YOY-+36.461
TTM36.4615Y31.467+4.994
5Y31.46710Y56.046-24.578
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ145.8453.235+142.610
TTM36.4613.310+33.151
YOY-3.838-3.838
5Y31.4675.679+25.788
10Y56.0467.823+48.223

1.3. Liquidity of Syndax Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Syndax is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.00 means the company has $10.00 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Syndax Pharmaceuticals Inc:

  • The MRQ is 9.999. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.974. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.999TTM12.974-2.976
TTM12.974YOY15.046-2.072
TTM12.9745Y11.566+1.408
5Y11.56610Y9.705+1.861
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.9993.863+6.136
TTM12.9744.169+8.805
YOY15.0465.337+9.709
5Y11.5666.122+5.444
10Y9.7056.434+3.271
1.3.2. Quick Ratio

Measures if Syndax is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Syndax to the Biotechnology industry mean.
  • A Quick Ratio of 14.82 means the company can pay off $14.82 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Syndax Pharmaceuticals Inc:

  • The MRQ is 14.820. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 22.593. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ14.820TTM22.593-7.773
TTM22.593YOY25.741-3.148
TTM22.5935Y19.052+3.541
5Y19.05210Y16.211+2.841
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.8203.504+11.316
TTM22.5933.991+18.602
YOY25.7415.371+20.370
5Y19.0526.088+12.964
10Y16.2116.395+9.816

1.4. Solvency of Syndax Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Syndax assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Syndax to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Syndax assets are financed with 9.6% credit (debt) and the remaining percentage (100% - 9.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Syndax Pharmaceuticals Inc:

  • The MRQ is 0.096. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.080. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.096TTM0.080+0.015
TTM0.080YOY0.086-0.005
TTM0.0805Y0.202-0.122
5Y0.20210Y0.351-0.149
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0960.339-0.243
TTM0.0800.337-0.257
YOY0.0860.271-0.185
5Y0.2020.368-0.166
10Y0.3510.388-0.037
1.4.2. Debt to Equity Ratio

Measures if Syndax is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Syndax to the Biotechnology industry mean.
  • A Debt to Equity ratio of 10.6% means that company has $0.11 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Syndax Pharmaceuticals Inc:

  • The MRQ is 0.106. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.088. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.106TTM0.088+0.018
TTM0.088YOY0.094-0.007
TTM0.0885Y0.304-0.216
5Y0.30410Y0.534-0.230
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1060.392-0.286
TTM0.0880.403-0.315
YOY0.0940.335-0.241
5Y0.3040.427-0.123
10Y0.5340.461+0.073

2. Market Valuation of Syndax Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Syndax generates.

  • Above 15 is considered overpriced but always compare Syndax to the Biotechnology industry mean.
  • A PE ratio of -6.33 means the investor is paying $-6.33 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Syndax Pharmaceuticals Inc:

  • The EOD is -6.029. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.334. Based on the earnings, the company is expensive. -2
  • The TTM is -8.309. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.029MRQ-6.334+0.305
MRQ-6.334TTM-8.309+1.976
TTM-8.309YOY-12.255+3.946
TTM-8.3095Y-12.299+3.990
5Y-12.29910Y-10.559-1.740
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.029-2.300-3.729
MRQ-6.334-2.656-3.678
TTM-8.309-2.718-5.591
YOY-12.255-4.145-8.110
5Y-12.299-6.258-6.041
10Y-10.559-6.315-4.244
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Syndax Pharmaceuticals Inc:

  • The EOD is -10.567. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.101. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.503. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.567MRQ-11.101+0.534
MRQ-11.101TTM-10.503-0.598
TTM-10.503YOY-15.075+4.571
TTM-10.5035Y-14.126+3.623
5Y-14.12610Y-13.150-0.976
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.567-2.974-7.593
MRQ-11.101-3.306-7.795
TTM-10.503-3.508-6.995
YOY-15.075-5.613-9.462
5Y-14.126-8.378-5.748
10Y-13.150-8.873-4.277
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Syndax is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.31 means the investor is paying $3.31 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Syndax Pharmaceuticals Inc:

  • The EOD is 3.154. Based on the equity, the company is fair priced.
  • The MRQ is 3.313. Based on the equity, the company is fair priced.
  • The TTM is 3.828. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.154MRQ3.313-0.159
MRQ3.313TTM3.828-0.515
TTM3.828YOY4.781-0.953
TTM3.8285Y8.202-4.374
5Y8.20210Y7.184+1.019
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.1541.914+1.240
MRQ3.3132.116+1.197
TTM3.8282.097+1.731
YOY4.7812.881+1.900
5Y8.2023.550+4.652
10Y7.1843.936+3.248
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Syndax Pharmaceuticals Inc.

3.1. Institutions holding Syndax Pharmaceuticals Inc

Institutions are holding 106.646% of the shares of Syndax Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Wellington Management Company LLP8.92740.03067585221-57225-0.7488
2023-12-31BlackRock Inc8.25690.00397015548113291219.2586
2023-12-31Kynam Capital Management, LP6.661513.55095660000206000057.2222
2023-12-31State Street Corporation5.90380.00535016224141557639.3145
2023-12-31Vanguard Group Inc5.10250.0021433535371805119.8505
2023-12-31venBio Select Advisor LLC4.96931.26034222222166666765.2174
2023-12-31Avidity Partners Management LP4.64893.11083950000112900040.0213
2023-12-31Eversept Partners, LLC3.98196.4232338324478699930.313
2023-09-30Partner Fund Management LP3.19571.8572271523554279824.9857
2023-12-31T. Rowe Price Investment Management,Inc.3.1910.038127112531644705154.2082
2023-12-31Goldman Sachs Group Inc2.94460.00492501896123414897.3496
2023-12-31Marshall Wace Asset Management Ltd2.47380.076921019111497949248.0204
2023-09-30Point72 Asset Management, L.P.2.46480.0887209420185940169.5984
2023-12-31Orbimed Advisors, LLC2.05850.7548174900046500036.215
2023-12-31Morgan Stanley - Brokerage Accounts1.95880.003216643061114277202.5851
2023-12-31Woodline Partners LP1.81750.3629154421615101494432.8793
2023-12-31Geode Capital Management, LLC1.80670.0035153505517413512.7954
2023-12-31Kingdon Capital Management LLC1.75672.021149258614925860
2023-12-31Franklin Resources Inc1.59230.0137135290513529050
2023-12-31Cormorant Asset Management, LLC1.38291.2127117500011750000
Total 75.095530.824763805376+21915033+34.3%

3.2. Funds holding Syndax Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Health Care Inv5.00130.19784249352115727037.4269
2024-02-29SPDR® S&P Biotech ETF4.46231.12223791374708601.9046
2024-02-29Vanguard Total Stock Mkt Idx Inv2.8160.00362392625-11654-0.4847
2024-02-29iShares Russell 2000 ETF1.91940.06131630808-267-0.0164
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.32880.02591129060-1135-0.1004
2023-12-31T. Rowe Price Small-Cap Value1.03350.179487810023500036.5418
2024-02-29Wellington Global Hlthcr Eq USD G Ac0.79670.6038676921-138585-16.9937
2023-12-31Fidelity Small Cap Index0.78280.0566665125175332.7074
2023-12-31Candriam Global Equities Oncology0.77210.7635656000416000173.3333
2024-02-29Belfius Equities Cure C Cap0.77210.814165600000
2024-02-29Franklin Biotechnology Discv A(acc)USD0.73910.7976628009299095.0007
2023-12-31Biotech Growth Ord0.6883.013958460010160021.0352
2024-02-29iShares Biotechnology ETF0.68760.1801584228-2630-0.4481
2023-12-31T. Rowe Price US Small-Cap Core Equity0.58290.11284952544952540
2023-12-31T. Rowe Price Small-Cap Stock0.58290.11314952544952540
2024-02-29iShares Russell 2000 Growth ETF0.57550.101488964-569-0.1162
2024-02-29Franklin Small Cap Growth Adv0.51810.355844020053001.2187
2023-12-31Franklin US Small Cap Growth Equity0.51190.3394349004349000
2024-01-31Fidelity Extended Market Index0.50180.024442634347891.136
2024-02-29Candriam Eqs L Biotech C USD Cap0.48840.591941500000
Total 25.56129.457821718117+3308829+15.2%

3.3. Insider Transactions

Insiders are holding 0.728% of the shares of Syndax Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-08-09Briggs MorrisonSELL5285518.27
2023-08-02William MeurySELL8300020.46
2023-07-10Briggs MorrisonSELL5285520.4
2023-06-13Keith A GoldanSELL57722.31
2023-06-09Briggs MorrisonSELL5285521.18
2023-05-09Briggs MorrisonSELL5285521.41

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Syndax Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.2950.255+799%0.174+1220%0.295+678%0.160+1334%
Book Value Per Share--6.5235.146+27%4.537+44%3.017+116%1.857+251%
Current Ratio--9.99912.974-23%15.046-34%11.566-14%9.705+3%
Debt To Asset Ratio--0.0960.080+19%0.086+12%0.202-53%0.351-73%
Debt To Equity Ratio--0.1060.088+21%0.094+12%0.304-65%0.534-80%
Dividend Per Share----0%-0%-0%0.001-100%
Eps---0.853-0.616-28%-0.439-48%-0.275-68%-0.254-70%
Free Cash Flow Per Share---0.487-0.473-3%-0.394-19%-0.228-53%-0.163-66%
Free Cash Flow To Equity Per Share--2.5560.305+739%0.113+2165%0.295+768%0.167+1428%
Gross Profit Margin--1.2951.074+21%1.000+29%1.015+28%1.007+29%
Intrinsic Value_10Y_max---13.341--------
Intrinsic Value_10Y_min---21.933--------
Intrinsic Value_1Y_max---0.753--------
Intrinsic Value_1Y_min---1.246--------
Intrinsic Value_3Y_max---2.707--------
Intrinsic Value_3Y_min---4.590--------
Intrinsic Value_5Y_max---5.198--------
Intrinsic Value_5Y_min---8.837--------
Market Cap1747740417.280-5%1836104541.4401660650775.680+11%1828882473.600+0%1437658810.432+28%989508259.584+86%
Net Profit Margin---135.211-33.803-75%--100%-30.519-77%-37.802-72%
Operating Margin---135.093-33.773-75%--100%-30.259-78%-35.985-73%
Operating Ratio--145.84536.461+300%-+100%31.467+363%56.046+160%
Pb Ratio3.154-5%3.3133.828-13%4.781-31%8.202-60%7.184-54%
Pe Ratio-6.029+5%-6.334-8.309+31%-12.255+93%-12.299+94%-10.559+67%
Price Per Share20.570-5%21.61019.545+11%21.525+0%16.921+28%11.646+86%
Price To Free Cash Flow Ratio-10.567+5%-11.101-10.503-5%-15.075+36%-14.126+27%-13.150+18%
Price To Total Gains Ratio8.962-5%9.415-31.775+437%-60.561+743%-40.322+528%-42.572+552%
Quick Ratio--14.82022.593-34%25.741-42%19.052-22%16.211-9%
Return On Assets---0.118-0.107-9%-0.088-25%-0.098-17%-0.156+32%
Return On Equity---0.131-0.117-11%-0.097-26%-0.140+7%-0.232+78%
Total Gains Per Share--2.2950.255+799%0.174+1220%0.295+678%0.161+1328%
Usd Book Value--554196000.000437232000.000+27%385510000.000+44%256298650.000+116%157802875.000+251%
Usd Book Value Change Per Share--2.2950.255+799%0.174+1220%0.295+678%0.160+1334%
Usd Book Value Per Share--6.5235.146+27%4.537+44%3.017+116%1.857+251%
Usd Dividend Per Share----0%-0%-0%0.001-100%
Usd Eps---0.853-0.616-28%-0.439-48%-0.275-68%-0.254-70%
Usd Free Cash Flow---41349000.000-40150250.000-3%-33475000.000-19%-19368550.000-53%-13895900.000-66%
Usd Free Cash Flow Per Share---0.487-0.473-3%-0.394-19%-0.228-53%-0.163-66%
Usd Free Cash Flow To Equity Per Share--2.5560.305+739%0.113+2165%0.295+768%0.167+1428%
Usd Market Cap1747740417.280-5%1836104541.4401660650775.680+11%1828882473.600+0%1437658810.432+28%989508259.584+86%
Usd Price Per Share20.570-5%21.61019.545+11%21.525+0%16.921+28%11.646+86%
Usd Profit---72473000.000-51107000.000-29%-36718500.000-49%-22779050.000-69%-16969075.000-77%
Usd Revenue--536000.000134000.000+300%-+100%7163950.000-93%3718775.000-86%
Usd Total Gains Per Share--2.2950.255+799%0.174+1220%0.295+678%0.161+1328%
 EOD+2 -6MRQTTM+17 -17YOY+16 -185Y+18 -1610Y+20 -16

4.2. Fundamental Score

Let's check the fundamental score of Syndax Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.029
Price to Book Ratio (EOD)Between0-13.154
Net Profit Margin (MRQ)Greater than0-135.211
Operating Margin (MRQ)Greater than0-135.093
Quick Ratio (MRQ)Greater than114.820
Current Ratio (MRQ)Greater than19.999
Debt to Asset Ratio (MRQ)Less than10.096
Debt to Equity Ratio (MRQ)Less than10.106
Return on Equity (MRQ)Greater than0.15-0.131
Return on Assets (MRQ)Greater than0.05-0.118
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Syndax Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.759
Ma 20Greater thanMa 5022.013
Ma 50Greater thanMa 10022.662
Ma 100Greater thanMa 20021.591
OpenGreater thanClose20.430
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -806470-336-238-574119-455673218
Gross Profit  -1152-113-39-152149-3271268
Income Tax Expense  -2,885-2,047-4,9324,874-5855-34,9964,993



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets612,880
Total Liabilities58,684
Total Stockholder Equity554,196
 As reported
Total Liabilities 58,684
Total Stockholder Equity+ 554,196
Total Assets = 612,880

Assets

Total Assets612,880
Total Current Assets580,876
Long-term Assets32,004
Total Current Assets
Cash And Cash Equivalents 295,394
Short-term Investments 282,189
Net Receivables 1,227
Inventory 2,003
Other Current Assets 63
Total Current Assets  (as reported)580,876
Total Current Assets  (calculated)580,876
+/-0
Long-term Assets
Property Plant Equipment 1,495
Long Term Investments 29,829
Long-term Assets Other 680
Long-term Assets  (as reported)32,004
Long-term Assets  (calculated)32,004
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities58,096
Long-term Liabilities588
Total Stockholder Equity554,196
Total Current Liabilities
Short-term Debt 1,047
Accounts payable 17,193
Other Current Liabilities 888
Total Current Liabilities  (as reported)58,096
Total Current Liabilities  (calculated)19,128
+/- 38,968
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt588
Long-term Liabilities  (as reported)588
Long-term Liabilities  (calculated)588
+/-0
Total Stockholder Equity
Common Stock8
Retained Earnings -902,400
Accumulated Other Comprehensive Income 218
Other Stockholders Equity 1,456,370
Total Stockholder Equity (as reported)554,196
Total Stockholder Equity (calculated)554,196
+/-0
Other
Capital Stock8
Cash and Short Term Investments 577,583
Common Stock Shares Outstanding 72,521
Current Deferred Revenue38,968
Liabilities and Stockholders Equity 612,880
Net Debt -293,759
Net Invested Capital 554,196
Net Working Capital 522,780
Property Plant and Equipment Gross 1,906
Short Long Term Debt Total 1,635



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
1,510
0
0
0
17,061
13,083
9,660
12,326
12,816
0
0
102,839
89,903
136,259
127,856
117,729
109,013
97,667
134,666
124,493
137,186
119,957
105,370
96,467
83,938
99,392
87,390
76,381
63,525
105,155
192,628
179,309
300,613
279,672
263,059
239,503
449,657
422,222
406,437
359,687
497,236
459,826
431,340
399,224
612,880
612,880399,224431,340459,826497,236359,687406,437422,222449,657239,503263,059279,672300,613179,309192,628105,15563,52576,38187,39099,39283,93896,467105,370119,957137,186124,493134,66697,667109,013117,729127,856136,25989,903102,8390012,81612,3269,66013,08317,0610001,510
   > Total Current Assets 
0
0
0
0
14,544
9,750
5,171
11,917
12,444
0
0
101,271
88,007
135,767
127,379
117,267
108,510
97,057
134,167
123,971
133,442
119,306
104,696
95,846
83,346
97,633
85,775
74,850
62,331
104,206
191,807
177,432
298,864
278,947
262,555
238,252
448,396
420,056
392,287
357,631
481,271
441,511
409,080
380,974
580,876
580,876380,974409,080441,511481,271357,631392,287420,056448,396238,252262,555278,947298,864177,432191,807104,20662,33174,85085,77597,63383,34695,846104,696119,306133,442123,971134,16797,057108,510117,267127,379135,76788,007101,2710012,44411,9175,1719,75014,5440000
       Cash And Cash Equivalents 
537
0
0
0
10,104
6,840
4,680
11,589
10,009
0
0
54,214
23,179
23,187
14,441
12,753
23,844
22,356
22,988
20,732
35,168
27,981
32,204
26,705
33,769
58,116
26,666
30,581
24,609
44,629
53,611
56,356
115,243
64,386
68,041
71,433
221,965
188,773
120,239
71,377
74,356
57,517
97,275
94,550
295,394
295,39494,55097,27557,51774,35671,377120,239188,773221,96571,43368,04164,386115,24356,35653,61144,62924,60930,58126,66658,11633,76926,70532,20427,98135,16820,73222,98822,35623,84412,75314,44123,18723,17954,2140010,00911,5894,6806,84010,104000537
       Short-term Investments 
174
0
0
0
4,160
2,657
330
102
2,199
0
0
46,247
64,115
110,483
111,016
102,814
81,486
70,429
106,967
99,862
94,806
85,242
66,181
62,894
47,142
34,626
53,854
41,657
35,166
54,376
133,142
113,803
177,822
206,949
185,091
158,281
217,971
222,136
256,439
279,331
410,041
380,688
308,749
279,271
282,189
282,189279,271308,749380,688410,041279,331256,439222,136217,971158,281185,091206,949177,822113,803133,14254,37635,16641,65753,85434,62647,14262,89466,18185,24294,80699,862106,96770,42981,486102,814111,016110,48364,11546,247002,1991023302,6574,160000174
       Net Receivables 
0
0
0
0
0
0
0
0
35
0
0
258
258
345
270
199
306
210
419
572
377
325
252
254
253
223
208
216
116
167
222
228
175
279
433
182
429
158
13,512
4,949
4,057
2,072
534
4,195
1,227
1,2274,1955342,0724,0574,94913,512158429182433279175228222167116216208223253254252325377572419210306199270345258258003500000000
       Inventory 
0
0
0
0
0
0
0
0
51
0
0
354
264
1,600
1,464
1,221
2,410
3,468
3,069
1,694
-1,442
3,538
4,139
4,511
1,053
3,565
4,043
1,543
1,677
4,303
4,440
6,723
5,283
7,206
8,817
8,115
7,651
2,269
1,914
1,822
-4,251
-9,685
2,243
2,681
2,003
2,0032,6812,243-9,685-4,2511,8221,9142,2697,6518,1158,8177,2065,2836,7234,4404,3031,6771,5434,0433,5651,0534,5114,1393,538-1,4421,6943,0693,4682,4101,2211,4641,600264354005100000000
   > Long-term Assets 
0
0
0
0
2,517
3,333
4,489
409
372
0
0
1,568
1,896
492
477
462
503
610
499
522
3,744
651
674
621
592
1,759
1,615
1,531
1,194
949
821
1,877
1,749
725
504
1,251
1,261
2,166
14,150
2,056
15,965
18,315
22,260
18,250
32,004
32,00418,25022,26018,31515,9652,05614,1502,1661,2611,2515047251,7491,8778219491,1941,5311,6151,7595926216746513,7445224996105034624774921,8961,568003724094,4893,3332,5170000
       Property Plant Equipment 
20
0
0
0
40
36
33
29
33
0
0
70
88
275
304
283
260
234
260
286
267
422
415
396
373
1,558
1,414
1,130
997
867
739
610
482
610
504
1,251
1,261
1,139
1,030
1,175
1,059
946
1,981
1,741
1,495
1,4951,7411,9819461,0591,1751,0301,1391,2611,2515046104826107398679971,1301,4141,558373396415422267286260234260283304275887000332933364000020
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,246
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,125
0
5,469
16,561
19,483
15,705
29,829
29,82915,70519,48316,5615,469012,125000000000000000003,24600000000000000000000
       Long-term Assets Other 
0
0
0
0
2,477
3,297
4,456
380
339
0
0
1,498
1,808
217
173
179
243
376
239
236
231
229
259
225
219
201
201
401
197
82
82
1,267
1,267
115
338
1,093
983
1,027
995
881
9,437
808
796
804
680
6808047968089,4378819951,0279831,0933381151,2671,26782821974012012012192252592292312362393762431791732171,8081,498003393804,4563,2972,4770000
> Total Liabilities 
0
0
0
0
5,212
4,650
5,350
14,904
18,532
0
0
32,080
23,205
22,413
21,615
23,895
24,874
25,052
25,329
27,779
32,867
33,007
35,018
32,193
30,891
30,766
32,115
32,338
31,925
51,646
44,981
47,332
48,425
51,467
48,496
40,499
41,289
47,673
44,497
21,585
29,787
24,321
31,299
40,038
58,684
58,68440,03831,29924,32129,78721,58544,49747,67341,28940,49948,49651,46748,42547,33244,98151,64631,92532,33832,11530,76630,89132,19335,01833,00732,86727,77925,32925,05224,87423,89521,61522,41323,20532,0800018,53214,9045,3504,6505,2120000
   > Total Current Liabilities 
25,104
0
0
0
2,730
2,084
4,622
9,661
10,346
0
0
13,472
4,847
7,035
6,553
9,147
10,366
10,989
11,505
14,207
15,798
16,907
19,298
17,016
16,105
15,658
17,491
18,294
18,368
18,790
12,467
15,157
18,872
24,568
24,292
28,712
20,683
30,551
30,925
20,803
29,065
23,721
30,168
39,174
58,096
58,09639,17430,16823,72129,06520,80330,92530,55120,68328,71224,29224,56818,87215,15712,46718,79018,36818,29417,49115,65816,10517,01619,29816,90715,79814,20711,50510,98910,3669,1476,5537,0354,84713,4720010,3469,6614,6222,0842,73000025,104
       Short-term Debt 
0
0
0
0
0
0
0
5,307
6,449
0
0
8,175
1,858
3,373
3,526
5,694
6,381
0
0
10,584
11,835
12,607
12,319
11,988
13,014
525
530
478
478
480
427
373
2,601
5,108
7,427
9,858
361
3,899
7,513
475
439
459
968
1,006
1,047
1,0471,0069684594394757,5133,8993619,8587,4275,1082,60137342748047847853052513,01411,98812,31912,60711,83510,584006,3815,6943,5263,3731,8588,175006,4495,3070000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
1,449
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
525
0
0
0
0
0
0
2,285
4,632
7,030
9,489
0
3,568
7,212
0
0
0
0
0
0
0000007,2123,56809,4897,0304,6322,28500000052500000000000000001,44900000000
       Accounts payable 
776
0
0
0
1,077
805
928
397
354
0
0
1,240
1,452
2,225
1,588
2,010
2,375
2,741
3,362
2,246
2,232
2,590
5,297
3,180
1,439
4,350
2,276
6,757
6,178
8,998
1,832
3,836
3,508
6,529
3,624
5,122
5,669
8,231
6,438
7,115
4,350
8,057
10,978
6,049
17,193
17,1936,04910,9788,0574,3507,1156,4388,2315,6695,1223,6246,5293,5083,8361,8328,9986,1786,7572,2764,3501,4393,1805,2972,5902,2322,2463,3622,7412,3752,0101,5882,2251,4521,240003543979288051,077000776
       Other Current Liabilities 
2,985
0
0
0
1,653
1,279
3,694
151
166
0
0
2,837
317
217
219
223
390
7,028
6,923
157
158
193
165
331
135
9,266
13,168
9,542
10,195
7,795
8,691
9,431
11,246
11,414
11,724
188
1,889
18,421
16,974
13,213
24,276
15,205
534
768
888
88876853415,20524,27613,21316,97418,4211,88918811,72411,41411,2469,4318,6917,79510,1959,54213,1689,2661353311651931581576,9237,0283902232192173172,837001661513,6941,2791,6530002,985
   > Long-term Liabilities 
0
0
0
0
2,482
2,566
728
5,243
8,186
0
0
18,608
18,358
15,378
15,062
14,748
14,508
14,063
13,824
13,572
17,069
16,100
15,720
15,177
14,786
15,108
14,624
14,044
13,557
32,856
32,514
32,175
29,553
26,899
24,204
11,787
20,606
17,122
13,572
782
722
600
1,131
864
588
5888641,13160072278213,57217,12220,60611,78724,20426,89929,55332,17532,51432,85613,55714,04414,62415,10814,78615,17715,72016,10017,06913,57213,82414,06314,50814,74815,06215,37818,35818,608008,1865,2437282,5662,4820000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,792
19,896
20,006
17,834
15,602
13,323
10,989
19,895
16,479
12,994
0
0
0
0
0
0
00000012,99416,47919,89510,98913,32315,60217,83420,00619,89619,79200000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
-5,307
-6,449
0
0
-8,175
-1,858
-3,373
-3,526
-5,694
-6,381
0
0
-10,584
-11,835
-12,607
-12,319
-11,988
-13,014
830
725
525
419
306
240
172
-2,184
-4,572
-7,008
-8,691
711
-2,925
-6,634
782
722
600
1,131
864
588
5888641,131600722782-6,634-2,925711-8,691-7,008-4,572-2,184172240306419525725830-13,014-11,988-12,319-12,607-11,835-10,58400-6,381-5,694-3,526-3,373-1,858-8,17500-6,449-5,3070000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
243
232
223
288
148
214
267
310
312
15,720
15,177
14,786
7
7
6
5
4
3
12,169
11,719
11,297
10,881
798
711
643
578
782
0
600
1,131
0
0
001,131600078257864371179810,88111,29711,71912,16934567714,78615,17715,7203123102672141482882232322430000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
300
0
0
0
1,600
15,135
14,830
14,525
14,220
13,915
13,610
13,305
16,759
15,788
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000015,78816,75913,30513,61013,91514,22014,52514,83015,1351,60000030000000000
> Total Stockholder Equity
0
0
0
0
11,849
8,433
4,310
-2,578
-5,716
0
0
70,759
66,698
113,846
106,241
93,834
84,139
72,615
109,337
96,714
104,319
86,950
70,352
64,274
53,047
68,626
55,275
44,043
31,600
53,509
147,647
131,977
252,188
228,205
214,563
199,004
408,368
374,549
361,940
338,102
467,449
435,505
400,041
359,186
554,196
554,196359,186400,041435,505467,449338,102361,940374,549408,368199,004214,563228,205252,188131,977147,64753,50931,60044,04355,27568,62653,04764,27470,35286,950104,31996,714109,33772,61584,13993,834106,241113,84666,69870,75900-5,716-2,5784,3108,43311,8490000
   Common Stock
0
0
0
0
1
1
1
1
1
0
0
1
1
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
4
4
5
5
5
5
6
6
6
6
7
7
7
7
8
877776666555544333332222222222221100111110000
   Retained Earnings Total Equity00-778,781-734,1660-653,846-618,443-580,871-543,702-639,900-619,261-596,351-568,628-548,205-527,768-510,706-495,470-481,470-468,641-453,725-439,423-420,586-403,247-384,860-366,111-347,008-331,919-318,279-305,293-294,478-279,509-271,1510000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-170
-1
0
0
-185
0
0
17
28
228
192
100
56
-2
36
28
-143
-218
-89
-35
-25
8
58
25
-310
48
117
53
-4
9
17
11
45
-640
-1,335
-1,605
-806
-336
-574
-455
218
218-455-574-336-806-1,605-1,335-6404511179-45311748-31025588-25-35-89-218-1432836-256100192228281700-18500-1-1700000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
384,767
385,556
388,210
389,374
390,894
441,218
443,692
470,571
472,026
473,686
484,893
492,493
522,340
523,855
525,485
527,067
564,164
675,294
680,125
820,815
824,542
833,802
838,888
952,019
956,054
981,712
993,547
0
1,170,000
1,179,389
0
0
001,179,3891,170,0000993,547981,712956,054952,019838,888833,802824,542820,815680,125675,294564,164527,067525,485523,855522,340492,493484,893473,686472,026470,571443,692441,218390,894389,374388,210385,556384,7670000000000000
   Treasury Stock000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
170
-1
0
0
185
0
0
17
220
248,508
257,700
270,481
389,710
390,892
441,254
443,720
470,627
471,808
473,597
484,858
492,703
522,348
523,913
525,510
527,377
564,212
675,411
680,125
820,815
824,542
833,802
838,888
408,323
956,054
981,712
993,547
1,161,288
1,170,000
1,179,389
1,189,561
1,456,370
1,456,3701,189,5611,179,3891,170,0001,161,288993,547981,712956,054408,323838,888833,802824,542820,815680,125675,411564,212527,377525,510523,913522,348492,703484,858473,597471,808470,627443,720441,254390,892389,710270,481257,700248,508220170018500-11700000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-12
Gross Profit-12-12
 
Operating Income (+$)
Gross Profit-12
Operating Expense-229,942
Operating Income-229,954-229,954
 
Operating Expense (+$)
Research Development163,020
Selling General Administrative54,335
Selling And Marketing Expenses0
Operating Expense229,942217,355
 
Net Interest Income (+$)
Interest Income18,601
Interest Expense-208
Other Finance Cost-20
Net Interest Income18,413
 
Pretax Income (+$)
Operating Income-229,954
Net Interest Income18,413
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-209,360-250,548
EBIT - interestExpense = -230,162
-209,360
-209,152
Interest Expense208
Earnings Before Interest and Taxes (EBIT)-229,954-209,152
Earnings Before Interest and Taxes (EBITDA)-229,942
 
After tax Income (+$)
Income Before Tax-209,360
Tax Provision-0
Net Income From Continuing Ops-176,081-209,360
Net Income-209,360
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses229,954
Total Other Income/Expenses Net20,594-18,413
 

Technical Analysis of Syndax
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Syndax. The general trend of Syndax is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Syndax's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Syndax Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 21.42 < 24.38 < 24.84.

The bearish price targets are: 19.58 > 16.77 > 15.90.

Tweet this
Syndax Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Syndax Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Syndax Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Syndax Pharmaceuticals Inc. The current macd is -0.58874043.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Syndax price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Syndax. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Syndax price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Syndax Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartSyndax Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Syndax Pharmaceuticals Inc. The current adx is 14.38.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Syndax shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Syndax Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Syndax Pharmaceuticals Inc. The current sar is 21.59.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Syndax Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Syndax Pharmaceuticals Inc. The current rsi is 37.76. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Syndax Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartSyndax Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Syndax Pharmaceuticals Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Syndax price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Syndax Pharmaceuticals Inc Daily Stochastic Oscillator ChartSyndax Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Syndax Pharmaceuticals Inc. The current cci is -106.61405284.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Syndax Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartSyndax Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Syndax Pharmaceuticals Inc. The current cmo is -34.85583419.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Syndax Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartSyndax Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Syndax Pharmaceuticals Inc. The current willr is -86.228482.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Syndax Pharmaceuticals Inc Daily Williams %R ChartSyndax Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Syndax Pharmaceuticals Inc. The current atr is 0.84683256.

Syndax Pharmaceuticals Inc Daily Average True Range (ATR) ChartSyndax Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Syndax Pharmaceuticals Inc. The current obv is -5,894,250.

Syndax Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartSyndax Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Syndax Pharmaceuticals Inc. The current mfi is 35.91.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Syndax Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartSyndax Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Syndax Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Syndax Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Syndax Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.759
Ma 20Greater thanMa 5022.013
Ma 50Greater thanMa 10022.662
Ma 100Greater thanMa 20021.591
OpenGreater thanClose20.430
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Syndax with someone you think should read this too:
  • Are you bullish or bearish on Syndax? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Syndax? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Syndax Pharmaceuticals Inc

I send you an email if I find something interesting about Syndax Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Syndax Pharmaceuticals Inc.

Receive notifications about Syndax Pharmaceuticals Inc in your mailbox!